20th Nov 2008 07:00
Sinclair Pharma plc Annual Information Update
20 November 2008, Godalming, UK: In accordance with the requirements of Prospectus Rule 5.2 issued by the Financial Services Authority, Sinclair Pharma plc submits its annual information update, which refers to information that has been published or made available to the public for the period from 16 November 2007 to 15 November 2008.
The information referred to in this announcement was current at the time the information was published and some information may now be out of date.
1. Announcements made via a Regulatory Information Service
Date Announcement 14/11/2008 Additional Listing 11/11/2008 Interim Management Statement
05/11/2008 Appointment of Vice President of Business Development
04/11/2008 Correction : 2008 Annual Report and Accounts 03/11/2008 2008 Annual Report and Accounts 03/11/2008 Sinclair Pharma's Non-Executive Chairman 31/10/2008 Second Price Monitoring Extn 31/10/2008 Price Monitoring Extension 31/10/2008 Statement re Funding Update 31/10/2008 Total Voting Rights 22/10/2008 Update on Strategic Opportunity 01/10/2008 Investec Bank (UK) - EPT Disclosure 01/10/2008 Sinclair Pharma Preliminary Results 30/09/2008 Offer Talks Terminated
29/09/2008 Gartmore Investment Management Ltd - Rule 8.3 - Sinclair
Pharma plc
23/09/2008 Gartmore Investment Management Ltd - Rule 8.3 - Sinclair
Pharma
22/09/2008 Gartmore Investment Management Ltd - Rule 8.3 - Sinclair
Pharma 22/09/2008 Landsbanki Sec UK - EPT Disclosure
19/09/2008 Gartmore Investment Management Ltd - Rule 8.3 - Sinclair
Pharma 19/09/2008 Sinclair Pharma: Date of Preliminary Results 18/09/2008 Investec Bank (UK) - EPT Disclosure 18/09/2008 Landsbanki Sec UK - EPT Disclosure 17/09/2008 Landsbanki Sec UK - EPT Disclosure 17/09/2008 Investec Bank (UK) - EPT Disclosure 16/09/2008 Landsbanki Sec UK - EPT Disclosure 15/09/2008 Landsbanki Sec UK - EPT Disclosure
12/09/2008 Gartmore Investment Management Ltd - Rule 8.3 - Sinclair
Pharma 12/09/2008 Landsbanki Sec UK - EPT Disclosure
11/09/2008 Gartmore Investment Management Ltd - Rule 8.3 - Sinclair
Pharma plc 11/09/2008 Investec Bank (UK) - EPT Disclosure 11/09/2008 Landsbanki Sec UK - EPT Disclosure
10/09/2008 Gartmore Investment Management Ltd - Rule 8.3 - Sinclair
Pharma 10/09/2008 Landsbanki Sec UK - EPT Disclosure
04/09/2008 Gartmore Investment Management Ltd - Rule 8.3 - Sinclair
Pharma plc 04/09/2008 Landsbanki Sec UK - EPT Disclosure
01/09/2008 Gartmore Investment Management Ltd - Rule 8.3 - Sinclair
Pharma plc 01/09/2008 Landsbanki Sec UK - EPT Disclosure
29/08/2008 Gartmore Investment Management Ltd - Rule 8.3 - Sinclair
Pharma plc 29/08/2008 Total Voting Rights 29/08/2008 Landsbanki Sec UK - EPT Disclosure 19/08/2008 Landsbanki Sec UK - EPT Disclosure 18/08/2008 Landsbanki Sec UK - EPT Disclosure 18/08/2008 Investec Bank (UK) - EPT Disclosure 14/08/2008 Investec Bank (UK) - EPT Disclosure
13/08/2008 Cheviot Asset Mgmt - Rule 8.3- Sinclair Pharma Plc
13/08/2008 Landsbanki Sec UK - EPT Disclosure 13/08/2008 Investec Bank (UK) - EPT Disclosure 12/08/2008 Investec Bank (UK) - EPT Disclosure 12/08/2008 Landsbanki Sec UK - EPT Disclosure 11/08/2008 Blocklisting Interim Review 11/08/2008 Landsbanki Sec UK - EPT Disclosure 11/08/2008 Investec Bank (UK) - EPT Disclosure
08/08/2008 Gartmore Investment Management Ltd - Rule 8.3 - Sinclair
Pharma 08/08/2008 Landsbanki Sec UK - EPT Disclosure 08/08/2008 Investec Bank (UK) - EPT Disclosure 07/08/2008 Statement re share price movement 22/07/2008 Trading Statement 04/07/2008 Holding(s) in Company 27/06/2008 Sinclair signs first agreement in India 19/06/2008 Director/PDMR Shareholding 18/06/2008 Director/PDMR Shareholding 16/06/2008 Director/PDMR Shareholding 13/06/2008 Director/PDMR Shareholding 12/06/2008 Director/PDMR Shareholding 11/06/2008 Director/PDMR Shareholding 10/06/2008 Director/PDMR Shareholding
22/05/2008 Sinclair Pharma plc holds analyst day in Paris
14/05/2008 Interim Management Statement 22/04/2008 Director/PDMR Shareholding 16/04/2008 Director/PDMR Shareholding 04/04/2008 Director/PDMR Shareholding 04/04/2008 Director/PDMR Shareholding 03/04/2008 Director/PDMR Shareholding 01/04/2008 NOTIFICATION OF MAJOR INTERESTS IN SHARES 27/03/2008 Director/PDMR Shareholding 26/03/2008 Director/PDMR Shareholding 19/03/2008 Director/PDMR Shareholding 12/03/2008 Director/PDMR Shareholding 10/03/2008 NOTIFICATION OF MAJOR INTERESTS IN SHARES 07/03/2008 Director/PDMR Shareholding 03/03/2008 Director/PDMR Shareholding 27/02/2008 Half-year results 18/02/2008 Appointment of new broker 08/02/2008 Notice of Interim Results
29/01/2008 Sinclair Pharma announces EU product registration
04/12/2007 Annual Information Update 03/12/2007 AGM Statement 30/11/2007 Director/PDMR Shareholding
2. Documents filed at Companies House
Type Date Description 88(2)R 24/10/2008 Issue of 42,334 ordinary shares at 1 pence each on 3 October 2008 88(2)R 21/08/2008 Issue of 433,690 ordinary shares at 36.3 pence each on 3 August 2008 288a 02/01/2008 Appointment of Mr Jean-Charles Tschudin as a director AA 06/12/2007 Group of companies accounts made up to 30 June 2007 RES11 06/12/2007 Authority to allot shares 3 December 2007 Disapplication of pre-emption rights 3 December 2007 288b 03/12/2007 Resignation of Andrew Sinclair as a director 395 29/11/2007 Particulars of mortgage/charge 363s 22/11/2007 Annual Return
Copies of documents filed at Companies House can be obtained from Companies House website at www.companieshouse.gov.uk or Companies House, Crown Way, Cardiff, CF14 3UZ.
3. Additional documents, including those filed with the UKLA or provided to shareholders:
* Annual report and accounts for the year ended 30 June 2008 and Notice of Annual General Meeting * Interim report for the six months to 31 December 2007
All of the documents listed above can be obtained from the Company's website www.sinclairpharmair.com
- ends -
For further information please contact:
Sinclair Pharma plc Tel: +44 (0) 1483 410 600
Dr Michael Flynn, CEO
Jerry Randall, CFO
Mariyam Rawat, Communications & Investor relations [email protected]
Capital MS&L
Mary Clark, Anna Mitchell Tel +44 (0)20 7307 5340
Notes to Editors:
About Sinclair Pharma Plc www.sinclairpharma.com
Sinclair Pharma plc is an international specialty pharmaceutical company. It has a growing sales and marketing operation that is already present in France, Italy, UK, Spain and Portugal, and a complementary marketing partner network that spans more than 80 countries.
Sinclair has proven expertise in acquiring or developing commercially attractive and undervalued products, registering these products and bringing them to market within a short timeframe. Sinclair focuses on niche therapeutic areas and its current portfolio includes products for dermatological conditions and oral health.
"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward-looking statements due to a variety of factors.
vendorRelated Shares:
Sinclair Pharma